List of works - Charlie Gourley

A Phase 3 Trial of Bevacizumab in Ovarian Cancer ⬇️

scientific article published on December 29, 2011

A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer.

scientific article

A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol

scientific article

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

scientific article

Anterior Gradient-3: A novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models ⬇️

scientific article published on February 15, 2012

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer

scientific article

BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer

scientific article

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer

scientific article published on 10 April 2017

Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial

scientific article

Cisplatin and Doxorubicin Induce Distinct Mechanisms of Ovarian Follicle Loss; Imatinib Provides Selective Protection Only against Cisplatin ⬇️

scientific article published on July 29, 2013

Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer

scientific article

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study

scientific article published on 06 August 2013

Endocrine therapy in epithelial ovarian cancer

scientific article published on 14 December 2016

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.

scientific article published on 3 January 2018

Erratum to Genetic and molecular changes in ovarian cancer

scientific article published on May 2017

Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OC

scientific article published on 16 May 2017

First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series

scientific article published on 13 April 2010

Genetic and molecular changes in ovarian cancer

scientific article published on June 2016

Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer

scientific article

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas.

scientific article

Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions

scientific article published on 26 February 2019

HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.

scientific article

Hormone receptors and ovarian cancer survival ⬇️

scientific article published on July 9, 2013

ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemo

scientific article published on 23 October 2020

Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer

scientific article published on 19 December 2012

Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial

scientific article

Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer

scientific article published on 27 August 2014

Interventions for the treatment of borderline ovarian tumours

scientific article (publication date: 2010)

Interventions for the treatment of borderline ovarian tumours

scientific article

Low-grade epithelial ovarian cancer: a number of distinct clinical entities?

scientific article published on September 2015

Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ.

scientific article published on 18 December 2017

Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications

scientific article published on 10 December 2013

Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome

scientific article published on 05 October 2020

OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

scientific article published on 23 November 2017

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

scientific article

Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.

scientific article published on 08 April 2016

Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge

scientific article

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

scientific article published on 08 September 2016

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

scientific article published on 20 April 2010

Prediction of anti-angiogenesis escape

scientific article published on 31 December 2015

Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line

scientific article

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.

scientific article published on 8 November 2016

Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression.

scientific article

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

scientific article published on 28 July 2020

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

scientific article

Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.

scientific article

Structural Variants at the <i>BRCA1/2</i> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma

scientific article published on 19 March 2021

Targeted anti-vascular therapies for ovarian cancer: current evidence ⬇️

scientific article

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

scientific article published on May 2016

The molecular origin and taxonomy of mucinous ovarian carcinoma

scientific article published on 02 September 2019

The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer

scientific article published on 26 April 2016

The use of cisplatin to treat advanced-stage cervical cancer during pregnancy allows fetal development and prevents cancer progression: report of a case and review of the literature

scientific article published on February 2009

Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer

scientific article published on January 2016

Using serum CA125 to assess the activity of potential cytostatic agents in ovarian cancer

scientific article published on May 2014

WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3.

scientific article

WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis.

scientific article published on 13 January 2010

List of works by Charlie Gourley

A Phase 3 Trial of Bevacizumab in Ovarian Cancer ⬇️

A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer.

A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

Anterior Gradient-3: A novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models ⬇️

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer

BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer

Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial

Cisplatin and Doxorubicin Induce Distinct Mechanisms of Ovarian Follicle Loss; Imatinib Provides Selective Protection Only against Cisplatin ⬇️

Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study

Endocrine therapy in epithelial ovarian cancer

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.

Erratum to Genetic and molecular changes in ovarian cancer

Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OC

First-line therapy for ovarian cancer with carboplatin followed by paclitaxel-gemcitabine (SCOTROC5): a feasibility study and comparative analysis of the SCOTROC series

Genetic and molecular changes in ovarian cancer

Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas.

Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions

HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer.

Hormone receptors and ovarian cancer survival ⬇️

ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemo

Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer

Integrated collaborative care for comorbid major depression in patients with cancer (SMaRT Oncology-2): a multicentre randomised controlled effectiveness trial

Integrated collaborative care for major depression comorbid with a poor prognosis cancer (SMaRT Oncology-3): a multicentre randomised controlled trial in patients with lung cancer

Interventions for the treatment of borderline ovarian tumours

Interventions for the treatment of borderline ovarian tumours

Low-grade epithelial ovarian cancer: a number of distinct clinical entities?

Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase ζ.

Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implications

Molecular stratification of endometrioid ovarian carcinoma predicts clinical outcome

OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.

Ovarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a Challenge

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

Prediction of anti-angiogenesis escape

Prior knowledge transfer across transcriptional data sets and technologies using compositional statistics yields new mislabelled ovarian cell line

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer.

Rab25 and CLIC3 collaborate to promote integrin recycling from late endosomes/lysosomes and drive cancer progression.

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

Safety and utility of image-guided research biopsies in relapsed high-grade serous ovarian carcinoma-experience of the BriTROC consortium.

Structural Variants at the <i>BRCA1/2</i> Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma

Targeted anti-vascular therapies for ovarian cancer: current evidence ⬇️

The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin

The molecular origin and taxonomy of mucinous ovarian carcinoma

The safety and efficacy of olaparib therapy in patients with relapsed ovarian cancer

The use of cisplatin to treat advanced-stage cervical cancer during pregnancy allows fetal development and prevents cancer progression: report of a case and review of the literature

Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer

Using serum CA125 to assess the activity of potential cytostatic agents in ovarian cancer

WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3.

WWOX tumour suppressor gene polymorphisms and ovarian cancer pathology and prognosis.